IDEAYA Biosciences is a clinical-stage oncology company dedicated to the discovery and development of precision medicine therapies through targeted therapeutics. Their innovative approach leverages DNA sequencing and other molecular diagnostics to select patient populations that are most likely to benefit from their therapies. IDEAYA is particularly focused on oncogenic pathways and synthetic lethality—emerging targets in precision medicine. They maintain an extensive pipeline of clinical programs, along with strategic collaborations with leading pharmaceutical companies such as GSK, Amgen, Pfizer, and Gilead. IDEAYA's commitment to advancing cancer treatment is rooted in a collaborative and data-driven culture, fostering an environment where teamwork and scientific inquiry drive impactful innovations in oncology.